The Open Atherosclerosis & Thrombosis Journal
2012, 5 : 1-5Published online 2012 January 06. DOI: 10.2174/1876506801205010001
Publisher ID: TOATHERTJ-5-1
Adiponectin Level Predicts HDL-Cholesterol Level in Type 2 Diabetes
ABSTRACT
Background:
Atherosclerotic cardiovascular complications are the major causes of morbidity and mortality in Type 2 diabetic patients. Many studies have demonstrated that adiponectin has both anti-atherogenic and anti-diabetic properties. This study aims to examine the regulatory roles of serum adiponectin in a homogeneous Type 2 diabetic cohort.
Method:
Of a population of 1256 registered diabetic patients, 116 subjects (1) aged between 40 and 70 years, (2) from the Chinese population, (3) having had Type 2 diabetes for more than one year, and (4) having been taking gliclazide and metformin for more than 6 months were enrolled in the study. All subjects were assigned to one of the plasma adiponectin level categories according to the quartiles. The main outcome evaluated is the associations of plasma adiponectin level; which were evaluated using multiple linear regression analysis.
Results:
Adiponectin concentration was the only and main predictor of HDL-cholesterol level (β = 0.321, p = 0.002) after adjusting other factors for the homogeneous Type 2 diabetic subjects.
Conclusion:
These initial findings seem to denote a positive association between adiponectin concentration and HDLcholesterol level in Type 2 diabetes. Adiponectin concentration might be a valuable marker of artherosclerosis in Type 2 diabetic patients.